News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors: Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@icrinc.com

Aad
March 10, 2020 Sirnaomics to Showcase Data for Lead Product STP705 in Human Squamous Carcinoma Tumor Model at 2020 American Academy of Dermatology Annual Meeting

Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

Opt
March 4, 2020 Sirnaomics to Present at 5th Annual Oligonucleotide & Precision Therapeutics Congress

Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

February 10, 2020 Sirnaomics’ siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the…

Wuhan
January 24, 2020 Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV

Sirnaomics Inc. (“Sirnaomics”), a leading biopharmaceutical company in discovery and development of novel RNAi therapeutics, announced today…

January 13, 2020 Sirnaomics and Junshi Biosciences Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Tuoyi and RNAi in China and US

Gaithersburg, MD, USA, and Shanghai, China, January 13, 2020 — Sirnaomics Inc. (“Sirnaomics”), a leading biopharmaceutical company…

1 2 3 9